Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis
- 4 October 2018
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Anti-infective Therapy
- Vol. 16 (11) , 839-847
Abstract
Introduction Invasive candidiasis is the most common fungal infection affecting critically ill adults. International guidelines provide differing recommendations for first-line antifungal therapy, with echinocandins considered first-line in the majority. Amphotericin B has broad activity and low MIC resistance patterns across most Candida species, and guidance away from its use should be supported by the available evidence. Areas Covered A systematic literature review was conducted from August to September 2017 to determine whether treatment with echinocandins or other available drugs, namely voriconazole, confers a therapeutic or survival benefit over amphotericin B in critically ill adults with invasive candidiasis. Inclusion criteria were: 1) studies describing critically ill adults with invasive candidiasis, 2) studies describing therapeutic benefit or survival as an outcome, and 3) studies comparing amphotericin B, deoxycholate or lipid preparations, with any newer antifungal agent. 8 studies were included in the final review, incorporating 2352 unique patients. No difference in treatment efficacy or mortality outcomes in critically ill patients with invasive candidiasis receiving an amphotericin B formulation compared with those receiving an echinocandin or voriconazole was shown. Expert Commentary We conclude that in the existing literature, there is no evidence that choice between echinocandins, voriconazole, or amphotericin B formulations as first line therapy for critically ill adults with invasive candidiasis is associated with a therapeutic or survival benefit. Clinicians must therefore consider other factors in selection of first line therapyKeywords
Funding Information
- not funded
This publication has 46 references indexed in Scilit:
- Frequency of Decreased Susceptibility and Resistance to Echinocandins among Fluconazole-Resistant Bloodstream Isolates of Candida glabrataJournal of Clinical Microbiology, 2012
- Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomesJournal of Antimicrobial Chemotherapy, 2011
- Diagnostic Issues, Clinical Characteristics, and Outcomes for Patients with FungemiaJournal of Clinical Microbiology, 2011
- Recent Exposure to Caspofungin or Fluconazole Influences the Epidemiology of Candidemia: a Prospective Multicenter Study Involving 2,441 PatientsAntimicrobial Agents and Chemotherapy, 2011
- Treatment of candidemia in adult patients without neutropenia - an inconvenient truthCritical Care, 2011
- Management of invasive fungal infections: a role for polyenesJournal of Antimicrobial Chemotherapy, 2010
- Treatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin BCritical Care, 2009
- Clinical Presentation, Etiology, and Outcome of Infective Endocarditis in the 21st CenturyArchives of internal medicine (1960), 2009
- A cost‐effectiveness analysis of caspofungin vs. liposomal amphotericin B for treatment of suspected fungal infections in the UKEuropean Journal of Haematology, 2007
- Antifungal Resistance Trends Towards the Year 2000Drugs, 1997